A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 PROOF OF CONCEPT (POC) STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF NINTEDANIB SOLUTION FOR INHALATION (AP02) IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (AURA-IPF)
- Registry ID
- AP02-003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- AVALYN PHARMA INC
- Start date
- 2026-01-30
- Last update
- 2025-10-23
Conditions
- IDIOPATHIC PULMONARY FIBROSIS (IPF)
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL OF THE EFFICACY AND SAFETY OF MNKD-201 (NINTEDANIB DRY POWDER INHALATION) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS FOLLOWED BY AN OPEN-LABEL EXTENSION
- IDIOPATHIC PULMONARY FIBROSIS: A PHASE 2A PLATFORM STUDY OF INVESTIGATIONAL PRODUCTS FOR THE TREATMENT OF ADULT SUBJECTS
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL PIPE-791 IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS
- A MULTINATIONAL, LONG-TERM, OPEN-LABEL EXTENSION STUDY OF SUBJECTS WHO HAVE PARTICIPATED IN AVALYN PHARMA STUDIES OF INHALED ANTIFIBROTIC AGENTS (AP-LTE-008 [SAIL])
- A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE IIA TRIAL TO
EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF
BI 765423 ADMINISTERED INTRAVENOUSLY WITH OR WITHOUT STANDARD OF CARE IN PATIENTS
WITH IDIOPATHIC PULMONARY FIBROSIS
- A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF MTX-463 IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
View on source registry